Pharmaceutical - AstraZeneca, Anti-virals

Filter

Current filters:

AstraZenecaAnti-virals

Popular Filters

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

Flu vaccine innovation needed to protect children, says GlobalData health care expert

13-01-2013

The last time the USA confronted a flu season this early, the virus claimed the lives of nearly 50,000…

Anti-viralsAstraZenecaFluarixFluMistGlaxoSmithKlinePharmaceuticalResearchVaccines

Clinical briefs from Novartis, Gilead and AstraZeneca

13-11-2012

Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

UK to implement child flu vaccines program

25-07-2012

UK Health Secretary Andrew Lansley yesterday accepted recommendations from UK immunization experts to…

Anti-viralsAstraZenecaFluenzHealthcarePharmaceuticalVaccines

Trudeau Institute discovers how FluMist elicits protection

24-08-2011

New research from the USA-based Trudeau Institute may help to explain why live attenuated influenza vaccine…

Anti-viralsAstraZenecaFluMistPharmaceuticalResearchVaccines

Back to top